CY1121423T1 - Φαρμακευτικη συνθεση για την αντιμετωπιση ενος μεταβολικου συνδρομου - Google Patents

Φαρμακευτικη συνθεση για την αντιμετωπιση ενος μεταβολικου συνδρομου

Info

Publication number
CY1121423T1
CY1121423T1 CY20181101387T CY181101387T CY1121423T1 CY 1121423 T1 CY1121423 T1 CY 1121423T1 CY 20181101387 T CY20181101387 T CY 20181101387T CY 181101387 T CY181101387 T CY 181101387T CY 1121423 T1 CY1121423 T1 CY 1121423T1
Authority
CY
Cyprus
Prior art keywords
treatment
pharmaceutical composition
metabolic syndrome
obesity
dyslipidemia
Prior art date
Application number
CY20181101387T
Other languages
English (en)
Inventor
Mark Sommerfeld
Hans-Ludwig Schaefer
Oliver Boscheinen
Paul Habermann
Ercole Rao
Matthias Dreyer
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41718306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121423(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi filed Critical Sanofi
Publication of CY1121423T1 publication Critical patent/CY1121423T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η εφεύρεση προσανατολίζεται σε μια φαρμακευτική σύνθεση που περιέχει μια τουλάχιστον ένωση FGF-21 (αυξητικός παράγοντας ινοβλαστών 21), έναν τουλάχιστον αγωνιστή GLP-1R (υποδοχέας όμοιου με γλυκαγόνη πεπτιδίου-1) και προαιρετικά ένα τουλάχιστον αντιδιαβητικό φάρμακο και/ή έναν τουλάχιστον αναστολέα DPP-4 (διπεπτιδυλ πεπτιδάσης-4), για την αντιμετώπιση ενός τουλάχιστον μεταβολικού συνδρόμου και/ή της αθηροσκλήρυνσης, ειδικότερα του διαβήτη, της δυσλιπιδαιμίας, της παχυσαρκίας και/ή της νοσογόνου παχυσαρκίας.
CY20181101387T 2010-01-21 2018-12-21 Φαρμακευτικη συνθεση για την αντιμετωπιση ενος μεταβολικου συνδρομου CY1121423T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP10305070A EP2359843A1 (en) 2010-01-21 2010-01-21 Pharmaceutical composition for treating a metabolic syndrome
EP20140163127 EP2754449A1 (en) 2010-01-21 2011-01-21 Pharmaceutical composition for treating a metabolic syndrome
EP11700669.2A EP2525807B1 (en) 2010-01-21 2011-01-21 Pharmaceutical composition for treating a metabolic syndrome
PCT/EP2011/050793 WO2011089203A1 (en) 2010-01-21 2011-01-21 Pharmaceutical composition for treating a metabolic syndrome

Publications (1)

Publication Number Publication Date
CY1121423T1 true CY1121423T1 (el) 2020-05-29

Family

ID=41718306

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20151100146T CY1116026T1 (el) 2010-01-21 2015-02-12 Φαρμακευτικη συνθεση για την αντιμετωπιση των μεταβολικων συνδρομων
CY20181101387T CY1121423T1 (el) 2010-01-21 2018-12-21 Φαρμακευτικη συνθεση για την αντιμετωπιση ενος μεταβολικου συνδρομου

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20151100146T CY1116026T1 (el) 2010-01-21 2015-02-12 Φαρμακευτικη συνθεση για την αντιμετωπιση των μεταβολικων συνδρομων

Country Status (33)

Country Link
US (4) US20130203651A1 (el)
EP (7) EP2359843A1 (el)
JP (3) JP5925130B2 (el)
KR (2) KR20120123445A (el)
CN (1) CN102753192B (el)
AR (1) AR079939A1 (el)
AU (2) AU2011208650B2 (el)
BR (1) BR112012017949A2 (el)
CA (1) CA2787131A1 (el)
CL (1) CL2012002031A1 (el)
CO (1) CO6592082A2 (el)
CY (2) CY1116026T1 (el)
DK (2) DK3216459T3 (el)
ES (3) ES2703581T3 (el)
HK (2) HK1173073A1 (el)
HR (2) HRP20150029T1 (el)
HU (1) HUE041442T2 (el)
IL (2) IL220862A0 (el)
LT (1) LT3216459T (el)
MA (1) MA33931B1 (el)
MX (2) MX336751B (el)
NZ (1) NZ601306A (el)
PL (2) PL3216459T3 (el)
PT (2) PT2525807E (el)
RS (1) RS53742B1 (el)
RU (2) RU2593960C2 (el)
SG (2) SG182652A1 (el)
SI (2) SI3216459T1 (el)
TR (1) TR201820147T4 (el)
TW (2) TWI561241B (el)
UY (1) UY33194A (el)
WO (1) WO2011089203A1 (el)
ZA (1) ZA201204996B (el)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2349324T3 (en) 2008-10-17 2017-12-11 Sanofi Aventis Deutschland COMBINATION OF AN INSULIN AND A GLP-1 AGONIST
KR101836070B1 (ko) 2009-11-13 2018-03-09 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ－１ 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물
JP5973918B2 (ja) 2009-11-13 2016-08-23 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト及びメチオニンを含む薬学的組成物
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
EP2548570A1 (en) * 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US9458214B2 (en) * 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
KR20150043505A (ko) * 2012-09-07 2015-04-22 사노피 대사 증후군의 치료용 융합 단백질
ES2828505T3 (es) 2012-11-28 2021-05-26 Ngm Biopharmaceuticals Inc Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
IL292303A (en) 2012-12-27 2022-06-01 Ngm Biopharmaceuticals Inc Methods of regulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
EP3062881B1 (en) 2013-10-28 2019-10-02 NGM Biopharmaceuticals, Inc. Cancer models and associated methods
JP6837840B2 (ja) 2014-01-24 2021-03-10 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 結合タンパク質及びその使用方法
WO2015121457A1 (en) * 2014-02-13 2015-08-20 Westphal Sören Fgf-8 for use in treating diseases or disorders of energy homeostasis
US20170065678A1 (en) 2014-03-11 2017-03-09 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
PL3139948T3 (pl) * 2014-05-07 2020-08-10 Novo Nordisk A/S Leczenie cukrzycy z zastosowaniem glp-1 i anty-il-21
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN104383523A (zh) * 2014-10-22 2015-03-04 山西医科大学 Cjc-1131降糖药物在治疗阿尔茨海默病的用途
US10517929B2 (en) 2014-10-23 2019-12-31 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising FGF19 variants
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
US11370841B2 (en) 2016-08-26 2022-06-28 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
WO2018115401A1 (en) * 2016-12-22 2018-06-28 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
JP2018110304A (ja) 2016-12-28 2018-07-12 パナソニックＩｐマネジメント株式会社 監視システム、監視方法、及びプログラム
CN108570109B (zh) * 2017-03-14 2022-04-26 广东东阳光药业有限公司 包含免疫球蛋白Fc部分的双靶点融合蛋白
CA3089657A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
WO2019154189A1 (en) 2018-02-08 2019-08-15 Sunshine Lake Pharma Co., Ltd. Fgf21 variant, fusion protein and application thereof
EP3810183A1 (en) * 2018-06-21 2021-04-28 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
CN115322794A (zh) 2020-01-11 2022-11-11 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
KR20210149366A (ko) * 2020-06-02 2021-12-09 주식회사 고바이오랩 Icam-2에 결합하는 물질을 유효성분으로 포함하는 대사질환 예방 또는 치료용 약학 조성물
US12054551B2 (en) 2020-07-02 2024-08-06 Sanofi FGFR1/KLB targeting agonistic antigen-binding proteins and conjugates thereof with GLP-1R agonistic peptides
WO2022144021A1 (zh) * 2021-01-04 2022-07-07 华领医药技术（上海）有限公司 Dorzagliatin和胰高血糖素样肽-1类似物的药物组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK347086D0 (da) 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
EP0280534B1 (en) 1987-02-25 1993-04-21 Novo Nordisk A/S Novel insulin derivatives
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
KR100310122B1 (ko) 1993-09-17 2002-04-24 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 아실화된인슐린
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
JP2002112772A (ja) * 2000-07-10 2002-04-16 Takeda Chem Ind Ltd 新規ポリペプチドおよびそのｄｎａ
US6689385B2 (en) * 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
AU2002322394A1 (en) 2001-07-30 2003-02-17 Eli Lilly And Company Method for treating diabetes and obesity
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
AU2003273300A1 (en) * 2002-09-06 2004-03-29 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
MXPA05013564A (es) 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion.
KR20060135648A (ko) 2003-12-10 2006-12-29 일라이 릴리 앤드 캄파니 섬유모세포 성장인자 21의 뮤테인
EP1727559A1 (en) 2004-01-26 2006-12-06 Eli Lilly And Company Use of fgf-21 and a thiazolidinedione for treating type 2 diabetes
WO2005091944A2 (en) 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
WO2005113606A2 (en) 2004-05-13 2005-12-01 Eli Lilly And Company Fgf-21 fusion proteins
US7622445B2 (en) 2004-09-02 2009-11-24 Eli Lilly And Company Muteins of fibroblast growth factor 21
KR100854198B1 (ko) 2004-09-02 2008-08-26 일라이 릴리 앤드 캄파니 섬유아세포 성장 인자 21의 뮤테인
JP5948627B2 (ja) 2004-10-29 2016-07-20 レイショファーム ゲーエムベーハー 線維芽細胞成長因子（ｆｇｆ）のリモデリングと糖質ペグ化
WO2006065582A2 (en) 2004-12-14 2006-06-22 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP2068910A2 (en) * 2006-08-04 2009-06-17 Amylin Pharmaceuticals, Inc. Use of exendins and exendin agonists and glp-1 receptor agonists for altering lipoprotein particle size and subclass composition
AR064623A1 (es) * 2006-12-21 2009-04-15 Centocor Inc Uso de agonistas del receptor de glp -1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
CN104163864B (zh) * 2007-03-30 2017-08-01 Ambrx公司 经修饰fgf‑21多肽和其用途
JP2010535781A (ja) * 2007-08-03 2010-11-25 イーライ リリー アンド カンパニー 肥満に対する処置
GB0716385D0 (en) * 2007-08-22 2007-10-03 Camurus Ab Formulations
US20100286067A1 (en) 2008-01-08 2010-11-11 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
WO2010006214A1 (en) * 2008-07-09 2010-01-14 Ambrx, Inc. Fgf-21 neutralizing antibodies and their uses
MX2011011815A (es) * 2009-05-05 2012-01-27 Amgen Inc Mutantes fgf21 y usos de los mismos.
JP2012529463A (ja) * 2009-06-11 2012-11-22 ノヴォ ノルディスク アー／エス ２型糖尿病を治療するための、ｇｌｐ−１とｆｇｆ２１との組合せ
EP2548570A1 (en) * 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome

Also Published As

Publication number Publication date
AU2016244202A1 (en) 2016-11-03
SI3216459T1 (sl) 2019-02-28
PL2525807T3 (pl) 2015-04-30
CN102753192B (zh) 2015-09-23
JP6521880B2 (ja) 2019-05-29
JP2018095659A (ja) 2018-06-21
ES2930750T3 (es) 2022-12-21
US20150231210A1 (en) 2015-08-20
BR112012017949A2 (pt) 2017-06-27
SG182652A1 (en) 2012-08-30
ES2529612T3 (es) 2015-02-23
RS53742B1 (en) 2015-06-30
AU2016244202B2 (en) 2018-03-01
TWI623320B (zh) 2018-05-11
IL220862A0 (en) 2012-09-24
HRP20182158T1 (hr) 2019-02-22
TWI561241B (en) 2016-12-11
EP3607964B1 (en) 2022-08-31
RU2016124562A3 (el) 2019-09-20
RU2016124562A (ru) 2018-11-30
MX336751B (es) 2016-01-29
SG10201500465XA (en) 2015-03-30
WO2011089203A1 (en) 2011-07-28
EP2359843A1 (en) 2011-08-24
UY33194A (es) 2011-08-31
CL2012002031A1 (es) 2012-12-14
PT3216459T (pt) 2019-01-11
JP2016128483A (ja) 2016-07-14
EP3216459B1 (en) 2018-09-26
IL267980B (en) 2020-03-31
MX2012008092A (es) 2012-07-30
JP2013518035A (ja) 2013-05-20
NZ601306A (en) 2013-11-29
IL267980A (en) 2019-08-29
CY1116026T1 (el) 2017-01-25
DK2525807T3 (en) 2015-02-09
KR20120123445A (ko) 2012-11-08
EP3357503B1 (en) 2019-10-30
MX361922B (es) 2018-12-19
TW201703792A (zh) 2017-02-01
HUE041442T2 (hu) 2019-05-28
MA33931B1 (fr) 2013-01-02
DK3216459T3 (en) 2019-01-21
EP2525807B1 (en) 2014-11-12
LT3216459T (lt) 2019-01-10
HK1259492A1 (zh) 2019-11-29
EP3357503A1 (en) 2018-08-08
US20160279199A1 (en) 2016-09-29
CN102753192A (zh) 2012-10-24
AU2011208650A1 (en) 2012-08-09
RU2593960C2 (ru) 2016-08-10
HK1173073A1 (en) 2013-05-10
ES2703581T3 (es) 2019-03-11
EP2460527A1 (en) 2012-06-06
EP2754449A1 (en) 2014-07-16
TR201820147T4 (tr) 2019-01-21
US20180236033A1 (en) 2018-08-23
TW201141511A (en) 2011-12-01
EP2525807A1 (en) 2012-11-28
AU2011208650B2 (en) 2016-07-14
PL3216459T3 (pl) 2019-04-30
ZA201204996B (en) 2013-02-27
CO6592082A2 (es) 2013-01-02
KR20180049194A (ko) 2018-05-10
RU2732703C2 (ru) 2020-09-21
SI2525807T1 (sl) 2015-02-27
EP3216459A1 (en) 2017-09-13
PT2525807E (pt) 2015-02-04
AR079939A1 (es) 2012-02-29
HRP20150029T1 (en) 2015-03-27
RU2012135686A (ru) 2014-02-27
EP3607964A1 (en) 2020-02-12
US20130203651A1 (en) 2013-08-08
JP5925130B2 (ja) 2016-05-25
CA2787131A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
CY1121423T1 (el) Φαρμακευτικη συνθεση για την αντιμετωπιση ενος μεταβολικου συνδρομου
PE20150648A1 (es) Proteinas de fusion para el tratamiento de un sindrome metabolico
AR092873A1 (es) Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
CL2012003053A1 (es) Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad.
CY1119952T1 (el) Συνδυασμος μιας ινσουλινης και ενος glp-1-αγωνιστη
CY1121853T1 (el) Συνδυαστικη θεραπεια για την αγωγη του διαβητη
CL2013003688A1 (es) Peptido coagonista del receptor de glucagon/glp-1; conjugado de dicho peptido; composicion farmacéutica; uso del peptido para tratar una enfermedad seleccionada del grupo de síndrome metabólico, diabetes, obesidad, esteatosis hepática y una enfermedad neurodegenerativa.
CR11849A (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabólicos y obesidad
CL2010001496A1 (es) Compuestos derivados de (piridin-o pirimidin-)piperidina, agonistas de gpr119; composicion farmaceutica; y su uso para el tratamiento de la diabetes de tipo i, diabetes de tipo ii y enfermedades relacionadas tales como sindrome metabolico, dislipidemia y resistencia a la insulina.
CL2008003222A1 (es) Peptidos con actividad antagonista de glucagon y composicion farmaceutica que los comprende, utiles para el tratamiento de la hiperglicemia, para suprimir el apetito, reducir el aumento de peso y para tratar el desgaste catabolico.
EA201490521A1 (ru) Варианты фактора роста фибробластов 21
TN2012000215A1 (en) Pharmaceutical compositions comprising a g l p -1 agonist and methionine
CL2013002414A1 (es) Compuestos derivados de azabencimidazol ciclico, activadores de la proteina cinasa activada por amp; composicion farmaceutica que los comprende; y su uso para el tratamiento o enfermedad tal como diabetes tipo 2, hiperglicemia, sindrome metabolico, obesidad, hipercolesterolemia e hipertension.
ECSP088120A (es) Derivados de piridazinona como agonistas del receptorde la hormona tiroidea
CL2013003454A1 (es) Composicion farmacéutica para prevenir o tratar diabetes que comprende un conjugado de insulina de accion prolongada y un conjugado de peptido insulinotropico de accion prolongada.
MY180661A (en) Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
CL2008000017A1 (es) Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
CL2008000018A1 (es) Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
EA201170305A1 (ru) Аналоги глюкозозависимого инсулинотропного полипептида (gip), модифицированные по n-концу
CL2013002053A1 (es) Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct
CL2007003176A1 (es) Compuestos derivados de nicotinamida, inhibidores de 11betahsd1; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el sindrome metabolico, la diabetes tipo 2, obesidad o aterosclerosis.
DK1856090T3 (da) Substituerede thiophen-derivater som glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
CY1125273T1 (el) Ανταγωνιστης υποδοχεα glp-1 για χρηση στη θεραπεια συγγενους υπερινσουλινισμου
TH130088B (th) องค์ประกอบทางเภสัชกรรมสำหรับการรักษากลุ่มอาการเกี่ยวกับเมแทบอลิก
TH130088A (th) องค์ประกอบทางเภสัชกรรมสำหรับการรักษากลุ่มอาการเกี่ยวกับเมแทบอลิก